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ess: mcazzola@qubisoftSummary We conducted a randomized, crossover trial with tiotropium 18 mg once
daily (group A), and formoterol 12 mg twice daily (group B) over a 5-day period for
each drug, with a 10-day washout, in 20 COPD patients. At the end of each period,
patients inhaled both drugs separated by 180min in alternate sequence (group A:
tiotropium 18 mg+formoterol 12 mg; group B: formoterol 12 mg+tiotropium 18 mg).
FEV1 and FVC were measured at baseline and after 30, 60, 120, 180, 210, 240, 300
and 360min. FEV1 and FVC further improved after crossover with both sequences.
The mean maximal change in FEV1 over baseline was 0.226 L (0.154–0.298) after
tiotropium+formoterol and 0.228 L (0.165–0.291) after formoterol+tiotropium; the
mean maximal change in FEV1 over pre-inhalation the second drug value was 0.081 L
(0.029–0.133) after tiotropium+formoterol and 0.054 L (0.016–0.092) after formo-
terol+tiotropium. The mean maximal change in FVC over baseline was 0.519 L
(0.361–0.676) after tiotropium+formoterol and 0.495 L (0.307–0.683) after formo-
terol+tiotropium; the mean maximal change in FVC over pre-inhalation of the second
drug value was 0.159 L (0.048–0.270) after tiotropium+formoterol and 0.175 L
(0.083–0.266) after formoterol+tiotropium. The FEV1 AUCs0–360min were 62.70
(45.67–79.74) after tiotropium+formoterol and 69.20 (50.84–87.57) after formoter-
ol+tiotropium, the FEV1 AUCs0–180min were 24.70 (18.19–31.21) after tiotropium+-
formoterol and 29.74 (21.02–38.46) after formoterol+tiotropium, whereas the FEV1
AUCs180–360min were 15.70 (10.88–20.52) after tiotropium+formoterol and 11.71Elsevier Ltd. All rights reserved.
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Bronchodilator response to formoterol after regular tiotropium 525(7.21–16.21) after formoterol+tiotropium. Differences between the two treatments
were not statistically significant (P40.05). The addition of second different long-
acting bronchodilator to a regularly administered long-acting bronchodilator seems
to be to patient’s advantage.
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b2-agonists and anticholinergics are distinct classes
of drugs with differing mechanisms of action.
Therefore, it seems reasonable to expect that they
might have additive, complementary effects when
combined.1–5
For this reason, some studies have examined
various strategies for adding b2-agonists and antic-
holinergics in COPD. Unfortunately, they have
provided conflicting results.6
In this study, we have examined the potential of
an additive effect of a recommended dose of second
long-acting bronchodilator (tiotropium, which is an
anticholinergic agent, or formoterol, a b2-agonist) in
COPD patients under regular treatment with a long-
acting bronchodilator of a different class (formoter-
ol or tiotropium, respectively).Patients and methods
We conducted a randomized, crossover trial in 20
outpatients of either sex with moderate to severe
COPD, but in a stable phase of disease and partially
reversible airway obstruction, who gave their
informed consent. Inclusion criteria were: 450
years with a 20 year smoking history, DFEV1/
predicted FEV1 p12% following 200mg salbutamol,
post-bronchodilator FEV1o80% in combination with
an FEV1/FVCo70%. Patients were excluded if they
had any current clinical evidence of asthma as
primary diagnosis, allergic rhinitis, atopy, skin-test
positively or with a total blood eosinophil count over
400mm3, unstable respiratory disease requiring
oral/parenteral corticosteroids within 4 weeks prior
to commencing study, upper or lower respiratory
tract infection within 4 weeks of screening visit, and
coexisting cardiovascular or lung disorder.
The patients continued to take the permitted
medication for their COPD in stable doses, which
included inhaled steroids, and mucolytics. Nor oral
bronchodilator neither inhaled long-acting bronch-
odilator agent were permitted for one week before
and during the study, whereas inhaled short-acting
bronchodilator were not permitted for at least 24 h
prior to each test, respectively. Patients also
avoided consumption of cola drinks, coffee, tea,and smoking in the hours before and during the
investigation.
The study, which was conducted according to the
rules of the declaration of Helsinki, was performed
using a randomised, crossover design. All patients
gave written informed consent before any study
procedure was undertaken. They were randomised
into one of two treatment groups on test-day 1
after a baseline pulmonary function testing, and
were treated initially with tiotropium 18 mg once
daily (group A), or inhaled formoterol 12 mg twice
daily (group B) over a 5-day period for each drug,
with a 10-day washout. At the end of each period
(test-day 6), patients inhaled both drugs separated
by 180min in alternate sequence (group A: tiotro-
pium 18 mg+formoterol 12 mg; group B: formoterol
12 mg+tiotropium 18 mg), and serial pulmonary
function testing was performed. Tiotropium was
delivered via a breath-actuated powder inhaler
(Handihaler), whereas, formoterol was adminis-
tered via the hydrofluoroalkane Modulite inhaler.
Pulmonary function testing always started be-
tween 08:00 and 09:00 h. Spirometric testing was
performed according to the procedures described
in the American Thoracic Society’s 1994 update.7
Three acceptable forced expiratory manoeuvres
were performed in order to obtain two reproduci-
ble results for FVC and FEV1. The highest FEV1,
obtained from one or the other of the reproducible
curves, was kept for analysis. On test-day 6,
measurements were performed immediately before
inhalation of current treatment and after 30, 60,
120, 180, 210, 240, 300, and 360min.
Responses to the inhaled bronchodilators were
evaluated in a blinded fashion. The functional
indices’ increases from baseline after tiotropium
and formoterol were assessed. As an expression of
the total effect of each treatment, the areas under
the FEV1 time–response curves (AUC) were calculated
for each patient by means of the trapezoidal rule.
Mean responses were compared by multifactorial
analysis of variance (ANOVA) to establish any sig-
nificant overall effect between treatments on each
day. In the presence of a significant overall ANOVA,
Duncan’s multiple range testing with 95% confidence
limits was used to identify where differences were
significant. A probability level of Po0.05 was
considered as being of significance for all tests.
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Figure 2 Mean response curves following the sequential
inhalation of tiotropium (Tio) and formoterol (For) for
FVC. Arrow indicates the administration of the second
drug. * Po0.05, ** Po0.01 in the sequence tiotropium-
formoterol. y Po0.05, yy Po0.01, yyy Po0.001 in the
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All patients completed the trial. There was no
significant difference between the baseline spiro-
metric values of the two treatment groups both at
test-day 1 (P ¼ 0:946) and at test-day 6 (P ¼ 0:526).
The mean baseline FEV1 at the start of treatment
period was 1.137 L (95% CI: 0.958–1.315) for the
tiotropium group and 1.134 L (95% CI: 0.942–1.326)
for the formoterol group. On test-day 6, the mean
FEV1 trough response was 1.194 L (95% CI:
1.008–1.380) for tiotropium and 1.170 L (95% CI:
0.975–1.364) for formoterol.
Both tiotropium and formoterol produced a
significant maximal improvement (Po0.0001) in
pulmonary function over baseline (Figs. 1 and 2).
FEV1 and FVC further improved after crossover with
both sequences. Thirty minutes after inhalation of
the last dose of tiotropium, there was a statistically
significant increase of 0.099 L (95 CI: 0.062–0.138)
in FEV1 over baseline (Po0.0001). The same was
observed after inhalation of the last dose of
formoterol (0.166 L; CI 95: 0.064–0.168;
Po0.0002).
The mean maximal change in FEV1 over baseline
was 0.226 L (0.154–0.298) in group A and 0.228 L
(0.165–0.291) in group B (Fig. 1). The mean
maximal change in FEV1 over pre-inhalation the
second drug value was 0.081 L (95% CI:
0.029–0.133; P ¼ 0:0043) after tiotropium-formo-
terol and 0.054 L (95% CI: 0.016–0.092; P ¼ 0:0161)
after formoterol-tiotropium.
The mean maximal change in FVC over baseline
was 0.519 L (95% CI: 0.361–0.676) in group A and
0.495 L (95% CI: 0.307–0.683) in group B (Fig. 2).
The mean maximal change in FVC over pre-0 60 120 180 240 300 360
1.1
1.2
1.3
1.4
1.5
Tio-For
For-Tio
*
**** **
§ § §§
min
L
Figure 1 Mean response curves following the sequential
inhalation of tiotropium (Tio) and formoterol (For) for
FEV1. Arrow indicates the administration of the second
drug. *Po0.05, **Po0.01, ***Po0.001 in the sequence
tiotropium-formoterol. y Po0.05, yy Po0.01 in the
sequence formoteroltiotropium.inhalation of the second drug value was 0.159 L
(95% CI: 0.048–0.270; P=0.0074) after tiotropium-
formoterol and 0.175 L (95% CI: 0.083–0.266;
P=0.0008) after formoterol-tiotropium.
The FEV1 AUCs0360min were 66.38 (95% CI:
49.73–83.04) after tiotropium-formoterol and
70.18 (95% CI: 52.15–88.21) after formoterol-
tiotropium, the FEV1 AUCs0180min were 24.70
(18.19–31.21) in Group A and 29.74 (21.02–38.46)
in Group B, whereas the FEV1 AUCs180360min were
15.70 (10.88–20.52) after tiotropium-formoterol
and 11.71 (7.21–16.21) after formoterol-tiotropium
(Fig. 3).
All differences between the two treatments were
not statistically significant (P40.05).sequence formoterol-tiotropium.
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Figure 3 Mean FEV1 AUCs following the sequential
inhalation of tiotropium and formoterol.
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Significant improvement in pulmonary function has
been achieved by adding tiotropium or formoterol
at the recommended dosages in patients already in
regular treatment with formoterol or tiotropium,
respectively, with no statistically significant differ-
ence between the different sequences. The gain in
FEV1 was similar in the two studied series and,
although relatively small, it was likely useful for
subjects suffering from a chronic airway obstruc-
tion that is only partially irreversible.
Therefore, our results suggest that supplement-
ing a second different long-acting bronchodilator to
a regularly administered long-acting bronchodilator
seems to be to patient’s advantage in terms of
bronchodilation.
In a previous our trial, we documented that the
sequential administration of formoterol and oxitro-
pium bromide induced an improvement in pulmon-
ary function in a population of COPD patient similar
to that examined in the present trial.8 However,
prior administration of the long-acting b2-agonist
allowed a response to the anticholinergic drug,
which was higher that that observed when inhala-
tion of oxitropium was preceding that of formoter-
ol. We do not know if the diverse pharmacological
characteristics of tiotropium and oxitropium could
justify the different response that we have ob-
served in the two studies. In effect, a comparison
between these two anticholinergic agents is still
lacking in literature. In any case, it is also possible
that the regular treatment administered for several
days in this study, but not in the first study in which
oxitropium was only given in an acute manner,
could explain why we have been unable to record a
statistically significant difference between the two
sequences.
The present results seem to refute Karpel’s
documentation9 that the addition of a second
bronchodilator of a different class did not result
in further spirometric improvement in most of
patients with stable COPD. These findings were
independent of the class of short-acting agents
used, b2-agonist or antimuscarinic. On the contrary,
they confirm and enlarge the opinion of Newnham
et al.10 that inhaling an effective dose of b2-agonist
as initial therapy gives rise to an adequate
response, although the predominant vagal tone
would appear to prevent optimum achievable
dilatation being achieved. In fact, the subsequent
addition of an anticholinergic still elicits a further
small degree of bronchodilation.
In any case, it must be highlighted that also
Heimer et al.11 demonstrated some additional
bronchodilatory response when an anticholinergicagent (ipratropium bromide) 250 mg was given after
a b-agonist (terbutaline 2.5mg), but not when
terbutaline was given after ipratropium bromide.
Gross and Skorodin12 observed that when salbuta-
mol was given first, subsequent administration of
atropine methonitrate resulted in a further sig-
nificant increase in FEV1. Salbutamol did not bring
about any further improvement in FEV1 than had
been achieved with atropine. When both agents
were given at high doses, the improvement in FEV1
was similar to that found with atropine alone. Also
in the study of Douglas et al.,13 when salbutamol
was given until no further bronchodilation could be
achieved, subsequent inhalation of 80 mg ipratro-
pium resulted in a further increase in FEV1 and FVC.
On the other hand, when salbutamol was adminis-
tered 3 h after ipratropium, the FEV1 rose to higher
levels than after either agent alone.
We cannot exclude that the larger bronchodila-
tory response that we observed when a second
bronchodilator was given after the first one should
be justified by a carry over effect, considering that
both formoterol and tiotropium are long-lasting
bronchodilators. This consideration could justify
the discrepancies that we have observed between
the results of this study and those produced with
short-acting bronchodilators. Nonetheless, it is well
know that the mean peak bronchodilation with
both formoterol and tiotropium in COPD patients is
reached after 2–3 h,4 and we have documented
that the addition of a second bronchodilator added
3 h after the inhalation of the first agent could
amplify the maximum bronchodilation of the first
agent. This finding seems to be important because
it indicates the possibility that a patient who is
unable to perceive bronchodilation or must per-
form an exercise could use a second long-acting
bronchodilator that will assure a long-lasting
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